Harpoon Brewery’s Octoberfest is an annual event Bostonians have looked forward to each fall for the past 33 years. This year ...

Target dose of 12 mg demonstrates robust early activity and manageable tolerability profile:– 63% ORR, 16% cytokine release ...

Harpoon Therapeutics (HARP – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...

Harpoon Therapeutics Inc (NASDAQ: HARP) shares are trading lower after AbbVie Inc (NYSE: ABBV) chose not to exercise its ...

Going forward, Harpoon said the TriTAC multiple myeloma program will remain exclusively within the company as it plans to ...

Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced dosing of the ...

Harpoon Therapeutics said on Wednesday that AbbVie won't exercise its exclusive license option on Harpoon's HPN217 program. The South San Francisco, Calif.-based immuno-oncology company said that ...

The FTC Chair defines monopoly down to harpoon the giant retailer with antitrust suit.

A Taiwanese F-16 with a Harpoon missile. The Ukrainian air force’s future fleet of former Danish, Dutch and Norwegian Lockheed Martin F-16 fighters should significantly boost the air force’s ...

In a report released on September 15, William Maughan from Canaccord Genuity maintained a Buy rating on Harpoon Therapeutics (HARP – ...

Shares of Harpoon Therapeutics fell Wednesday after the company said AbbVie wouldn't exercise an exclusive license option on one of its treatments. The stock was down 7.3% to $6.06 after-hours, after ...

Target dose of 12 mg demonstrates robust early activity and manageable tolerability profile:- 63% ORR, 16% cytokine release syndrome (CRS), No ICANS - Phase 1 data set, including recommended Phase 2 ...